The role of ivabradine in improving myocardial perfusion, adding to the antianginal benefits

This article discusses the role of ivabradine in improvement of myocardial perfusion based on data drawn from relevant preclinical and clinical investigations. Experimental data suggest that heart rate reduction with ivabradine causes greater increase in duration of diastolic perfusion time and coronary flow compared with β-blockade due to absence of impairing of left ventricular contractility and coronary vasomotion. In consequence, the full benefits of heart rate reduction for improved coronary perfusion could be realized with ivabradine. Following experimental data, clinical studies demonstrated anti-ischaemic and antianginal efficacy of ivabradine in patients with stable coronary artery disease. These clinical benefits have been supported by recent clinical data on improvement of coronary flow reserve, and coronary collateral circulation with ivabradine supports the role of ivabradine as an important anti-ischaemic and antianginal agent in patients with angina in addition to other recommended therapies or revascularization.

Source: European Journal of Heart Failure Supplements - December 16, 2015 Category: Cardiology Authors: Vardas, P. E., Skalidis, E. I. Tags: Articles Source Type: research